Article Text

Download PDFPDF

4CPS-167 Current trends in the use of check-point inhibitors for non-small-cell lung cancer
  1. A Alvarez-Yuste,
  2. M Perez-Abanades,
  3. T Gallego-Aranda,
  4. E Lopez-Aspiroz,
  5. A Ibañez-Zurriaga,
  6. A Garcia-Peralo,
  7. G Escudero-Sanchez,
  8. P Duque-Tebar,
  9. A Morell-Baladron
  1. La Princesa University Hospital, Hospital Pharmacy, Madrid, Spain


Background and Importance Over the last years, immunotherapy has changed the treatment paradigm of non-small-cell lung cancer (NSCLC). The number of patients treated with immune check-point inhibitors (ICI): atezolizumab, durvalumab, pembrolizumab and nivolumab has dramatically increased.

Aim and Objectives To evaluate the current trends in the use of ICI for NSCLC in a third level hospital.

Material and Methods A retrospective observational study was conducted, including patients with NSCLC who had received treatment between 2016 and 2021 with chemotherapy or ICI (atezolizumab, durvalumab, nivolumab or pembrolizumab). The data collected was drug, date and number of administrations, days between each administration and clinical response.

Results During the study period, there were 606 patients being treated for NSCLC, and 254 of them received ICI (41.91%).

Conclusion and Relevance The total number of patients treated with ICI for NSCLC has increased constantly during this period of time (49.15% increase between 2016 and 2021). Moreover, immunotherapy entail the treatment of nearly half of the NSCLC patients.

During the time period studied, the use of nivolumab has decreased, favouring pembrolizumab, probably because of the rise of its new approved indications. Secondly, the number of patients who have received atezolizumab and durvalumab has kept comparable.

Abstract 4CPS-167 Table 1

Number of patients, administrations and days between each administration of ICI

We can see a significate decrease on the number of patients treated with an ICI between May 2020 and August 2020, possibly influenced by the decrease in the number of patients diagnosed with NSCLC during the COVID-19 pandemic.

The mean days between each ICI administration was slightly above the approved posology, possibly due to delays because of adverse effects.

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.